Products & Programs PharmacyCommercialMay 1, 2023

Clinical Criteria updates for specialty pharmacy are available

Effective for dates of service on and after August 1, 2023, the following Clinical Criteria were developed and might result in services that were previously covered but may now be found to be not medically necessary.

CC-0096

Asparagine Specific Enzymes

CC-0128

Tecentriq (atezolizumab)

CC-0131

Besponsa (inotuzumab ozogamicin)

CC-0233

Rebyota (fecal microbiota, live – jslm)

Access the Clinical Criteria document information at https://anthem.com/ms/pharmacyinformation/clinicalcriteria.html

The Anthem Blue Cross and Blue Shield (Anthem) prior authorization clinical review of non-oncology specialty pharmacy drugs will be managed by Anthem’s medical specialty drug review team. Drugs used for the treatment of oncology will be managed by Carelon Medical Benefits Management, Inc. *

* Carelon Medical Benefits Management, Inc. is an independent company providing utilization management services on behalf of the health plan.

GABCBS-CM-022598-23

PUBLICATIONS: May 2023 Provider News